Published in Neth Heart J on September 01, 2001
Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation (1995) 8.62
Mutations of the Connexin43 gap-junction gene in patients with heart malformations and defects of laterality. N Engl J Med (1995) 3.52
Chronic rapid atrial pacing. Structural, functional, and electrophysiological characteristics of a new model of sustained atrial fibrillation. Circulation (1995) 2.88
Microbubbles targeted to intercellular adhesion molecule-1 bind to activated coronary artery endothelial cells. Circulation (1998) 2.57
Structural changes of atrial myocardium due to sustained atrial fibrillation in the goat. Circulation (1997) 2.52
Verapamil reduces tachycardia-induced electrical remodeling of the atria. Circulation (1997) 2.44
Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. Circ Res (1997) 2.38
Immunocytochemical localization of rH1 sodium channel in adult rat heart atria and ventricle. Presence in terminal intercalated disks. Circulation (1996) 2.15
Altered pattern of connexin40 distribution in persistent atrial fibrillation in the goat. J Cardiovasc Electrophysiol (1998) 1.85
Electrical remodeling in atrial fibrillation. Time course and mechanisms. Circulation (1996) 1.75
Pacing-induced chronic atrial fibrillation impairs sinus node function in dogs. Electrophysiological remodeling. Circulation (1996) 1.74
Role of troponin I proteolysis in the pathogenesis of stunned myocardium. Circ Res (1997) 1.74
Differing sympathetic and vagal effects on atrial fibrillation in dogs: role of refractoriness heterogeneity. Am J Physiol (1997) 1.72
Impaired left atrial mechanical function after cardioversion: relation to the duration of atrial fibrillation. J Am Coll Cardiol (1994) 1.61
Molecular mechanisms underlying ionic remodeling in a dog model of atrial fibrillation. Circ Res (1999) 1.56
Functional mechanisms underlying tachycardia-induced sustained atrial fibrillation in a chronic dog model. Circulation (1997) 1.51
Alterations in potassium channel gene expression in atria of patients with persistent and paroxysmal atrial fibrillation: differential regulation of protein and mRNA levels for K+ channels. J Am Coll Cardiol (2001) 1.46
Atrial fibrillation produced by prolonged rapid atrial pacing is associated with heterogeneous changes in atrial sympathetic innervation. Circulation (2000) 1.42
Electrical remodeling of the human atrium: similar effects in patients with chronic atrial fibrillation and atrial flutter. J Am Coll Cardiol (1997) 1.41
Ion channel remodeling is related to intraoperative atrial effective refractory periods in patients with paroxysmal and persistent atrial fibrillation. Circulation (2001) 1.37
Localization of the Kv1.5 K+ channel protein in explanted cardiac tissue. J Clin Invest (1995) 1.35
Importance of refractoriness heterogeneity in the enhanced vulnerability to atrial fibrillation induction caused by tachycardia-induced atrial electrical remodeling. Circulation (1998) 1.33
Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans. Circulation (2000) 1.33
Myocardial cell death in fibrillating and dilated human right atria. J Am Coll Cardiol (1999) 1.30
Calcium-activated neutral protease and its endogenous inhibitor. Activation at the cell membrane and biological function. FEBS Lett (1987) 1.29
Chronic atrial fibrillation. Success of serial cardioversion therapy and safety of oral anticoagulation. Arch Intern Med (1997) 1.29
Pulsed Doppler evaluation of atrial mechanical function after electrical cardioversion of atrial fibrillation. J Am Coll Cardiol (1989) 1.27
Early recurrences of atrial fibrillation after electrical cardioversion: a result of fibrillation-induced electrical remodeling of the atria? J Am Coll Cardiol (1998) 1.22
Gene expression of proteins influencing the calcium homeostasis in patients with persistent and paroxysmal atrial fibrillation. Cardiovasc Res (1999) 1.17
Effect of verapamil and procainamide on atrial fibrillation-induced electrical remodeling in humans. Circulation (1997) 1.07
A comparison of the intracellular distribution of mu-calpain, m-calpain, and calpastatin in proliferating human A431 cells. Exp Cell Res (1992) 1.04
Role of intracellular sodium overload in the genesis of cardiac arrhythmias. J Cardiovasc Electrophysiol (1997) 0.99
Proteolysis of connexin43-containing gap junctions in normal and heat-stressed cardiac myocytes. Cardiovasc Res (1998) 0.96
Role of calcium-activated neutral protease (calpain) in cell death in cultured neonatal rat cardiomyocytes during metabolic inhibition. Circ Res (1995) 0.96
Failure in the rate adaptation of the atrial refractory period: its relationship to vulnerability. Int J Cardiol (1982) 0.96
Atrial contractile dysfunction after short-term atrial fibrillation is reduced by verapamil but increased by BAY K8644. Circulation (1996) 0.96
Calpain inhibitors as therapeutic agents in nerve and muscle degeneration. Ann N Y Acad Sci (1999) 0.90
Changes in ultrastructural calcium distribution in goat atria during atrial fibrillation. J Mol Cell Cardiol (2000) 0.88
Identification of the substrate of atrial vulnerability in patients with idiopathic atrial fibrillation. Circulation (2000) 0.85
Alterations in gene expression of proteins involved in the calcium handling in patients with atrial fibrillation. J Cardiovasc Electrophysiol (1999) 0.84
Cardiomyocyte troponin T immunoreactivity is modified by cross-linking resulting from intracellular calcium overload. Circulation (1996) 0.84
Regional and functional factors determining induction and maintenance of atrial fibrillation in dogs. Am J Physiol (1996) 0.84
G(s) and adenylyl cyclase in transverse tubules of heart: implications for cAMP-dependent signaling. Am J Physiol (1999) 0.83
Short-term effect of atrial fibrillation on atrial contractile function in humans. Circulation (1999) 0.83
Expression of heat shock protein after ischemic preconditioning in rabbit hearts. Jpn Circ J (1998) 0.81
Role of the Na(+)/H(+) exchanger in short-term atrial electrophysiological remodeling. Circulation (2000) 0.80
The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J (2003) 4.09
Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey. Lancet (2002) 2.61
QT lengthening and life-threatening arrhythmias associated with fexofenadine. Lancet (1999) 2.48
Changes in glomerular filtration rate after cardiac surgery with cardiopulmonary bypass in patients with mild preoperative renal dysfunction. Br J Anaesth (2008) 2.07
Impact of a short course in pharmacotherapy for undergraduate medical students: an international randomised controlled study. Lancet (1995) 1.97
Quality of life in patients with paroxysmal atrial fibrillation and its predictors: importance of the autonomic nervous system. Eur Heart J (2001) 1.87
Spinal cord stimulation in chronic intractable angina pectoris: a randomized, controlled efficacy study. Am Heart J (1998) 1.80
Prognostic value of the presence and development of atrial fibrillation in patients with advanced chronic heart failure. Eur Heart J (2000) 1.75
Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial. Eur Heart J (2003) 1.74
Systemic gene therapy with interleukin-13 attenuates renal ischemia-reperfusion injury. Kidney Int (2008) 1.64
The fibrosis marker galectin-3 and outcome in the general population. J Intern Med (2011) 1.62
Endothelin system in human persistent and paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol (2001) 1.55
A-type lamins are essential for TGF-beta1 induced PP2A to dephosphorylate transcription factors. Hum Mol Genet (2005) 1.55
Regional myocardial blood flow reserve impairment and metabolic changes suggesting myocardial ischemia in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol (2000) 1.48
Prediction of 6 months left ventricular dilatation after myocardial infarction in relation to cardiac morbidity and mortality. Application of a new dilatation model to GISSI-3 data. Eur Heart J (2002) 1.48
Alterations in potassium channel gene expression in atria of patients with persistent and paroxysmal atrial fibrillation: differential regulation of protein and mRNA levels for K+ channels. J Am Coll Cardiol (2001) 1.46
Isoform diversity of the inositol trisphosphate receptor in cell types of mouse origin. Biochem J (1997) 1.45
Paroxysmal atrial fibrillation, quality of life and neuroticism. Neth J Med (2005) 1.45
Microalbuminuria is independently associated with ischaemic electrocardiographic abnormalities in a large non-diabetic population. The PREVEND (Prevention of REnal and Vascular ENdstage Disease) study. Eur Heart J (2000) 1.42
Effect of very early angiotensin-converting enzyme inhibition on left ventricular dilation after myocardial infarction in patients receiving thrombolysis: results of a meta-analysis of 845 patients. FAMIS, CAPTIN and CATS Investigators. J Am Coll Cardiol (2000) 1.40
[Hormonal supplement therapy in women: effects on the cardiovascular system]. Ned Tijdschr Geneeskd (2001) 1.39
Effects of aspirin on angiotensin-converting enzyme inhibition and left ventricular dilation one year after acute myocardial infarction. Am J Cardiol (1998) 1.39
[Beta-blocking drugs indicated in patients with heart failure]. Ned Tijdschr Geneeskd (2003) 1.39
Endothelium dependent relaxation in two different models of chronic heart failure and the effect of ibopamine. Cardiovasc Res (1993) 1.38
Clinical and neurohumoral differences between spirapril and captopril in mild to moderate chronic congestive heart failure. J Card Fail (1997) 1.38
[Cardiac sarcoidosis: improved prognosis through new diagnostic tests and treatment]. Ned Tijdschr Geneeskd (2005) 1.37
Electrophysiological changes of angiotensin-converting enzyme inhibition after myocardial infarction. J Card Fail (2000) 1.37
Ion channel remodeling is related to intraoperative atrial effective refractory periods in patients with paroxysmal and persistent atrial fibrillation. Circulation (2001) 1.37
Human SCN5A gene mutations alter cardiac sodium channel kinetics and are associated with the Brugada syndrome. Cardiovasc Res (1999) 1.34
N-terminal pro B-type natriuretic peptide levels predict newly detected atrial fibrillation in a population-based cohort. Neth Heart J (2008) 1.26
Angiotensin-(1-7) is a modulator of the human renin-angiotensin system. Hypertension (1999) 1.23
Hereditary muscular dystrophies and the heart. Neuromuscul Disord (2010) 1.21
Angiotensin II type 1 receptor A1166C gene polymorphism is associated with an increased response to angiotensin II in human arteries. Hypertension (2000) 1.21
Supraventricular tachycardia mimicking ventricular tachycardia during flecainide treatment. Am J Cardiol (1988) 1.21
Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. Int J Cardiol (2006) 1.20
Deletion-type allele of the angiotensin-converting enzyme gene is associated with progressive ventricular dilation after anterior myocardial infarction. Captopril and Thrombolysis Study Investigators. J Am Coll Cardiol (1995) 1.20
Gene expression of proteins influencing the calcium homeostasis in patients with persistent and paroxysmal atrial fibrillation. Cardiovasc Res (1999) 1.17
Atrial tissue Doppler imaging for prediction of new-onset atrial fibrillation. Heart (2008) 1.17
Reduction of reperfusion arrhythmias in the ischemic isolated rat heart by angiotensin converting enzyme inhibitors: a comparison of captopril, enalapril, and HOE 498. J Cardiovasc Pharmacol (1986) 1.11
Acute intervention with captopril during thrombolysis in patients with first anterior myocardial infarction. Results from the Captopril and Thrombolysis Study (CATS). Eur Heart J (1994) 1.05
Telomere length loss due to smoking and metabolic traits. J Intern Med (2013) 1.04
Blood cell dynamics during hibernation in the European Ground Squirrel. Vet Immunol Immunopathol (2010) 1.01
Atrial extrasystoles after exercise predict atrial fibrillation in patients with left ventricular hypertrophy. Heart (2006) 1.00
Gender-specific correlations of plasminogen activator inhibitor-1 and tissue plasminogen activator levels with cardiovascular disease-related traits. J Thromb Haemost (2006) 0.98
Efficacy, safety, and determinants of conversion of atrial fibrillation and flutter with oral amiodarone. Am J Cardiol (1997) 0.96
Myogenic constriction is increased in mesenteric resistance arteries from rats with chronic heart failure: instantaneous counteraction by acute AT1 receptor blockade. Br J Pharmacol (2003) 0.95
Effects of angiotensin II and captopril on inducible sustained ventricular tachycardia two weeks after myocardial infarction in the pig. J Cardiovasc Pharmacol (1989) 0.95
Antithrombotic drug prescription in atrial fibrillation and its rationale among general practitioners, internists and cardiologists in The Netherlands--The EXAMINE-AF study. A questionnaire survey. Int J Clin Pract (2007) 0.95
Acute conversion of atrial fibrillation to sinus rhythm: clinical efficacy of flecainide acetate. Comparison of two regimens. Eur Heart J (1988) 0.95
The future of atrial fibrillation therapy: intervention on heat shock proteins influencing electropathology is the next in line. Neth Heart J (2015) 0.94
Rat abdominal aortic stenting: a simple model displaying in-stent restenosis. Am J Cardiol (2002) 0.94
Inotropic effects of propofol, thiopental, midazolam, etomidate, and ketamine on isolated human atrial muscle. Anesthesiology (1996) 0.94
Recurrent and founder mutations in the Netherlands-Phospholamban p.Arg14del mutation causes arrhythmogenic cardiomyopathy. Neth Heart J (2013) 0.94
Hydrogen sulfide restores a normal morphological phenotype in Werner syndrome fibroblasts, attenuates oxidative damage and modulates mTOR pathway. Pharmacol Res (2013) 0.93
Improving guideline adherence in the treatment of atrial fibrillation by implementing an integrated chronic care program. Neth Heart J (2010) 0.91
Effects of quinapril on clinical outcome after coronary artery bypass grafting (The QUO VADIS Study). QUinapril on Vascular Ace and Determinants of Ischemia. Am J Cardiol (2001) 0.90
Cardiac involvement of Churg Strauss syndrome demonstrated by magnetic resonance imaging. Clin Exp Rheumatol (2004) 0.90
Association between reduced heart rate variability and left ventricular dilatation in patients with a first anterior myocardial infarction. CATS Investigators. Captopril and Thrombolysis Study. Br Heart J (1994) 0.90
Effect of dexamethasone on perioperative renal function impairment during cardiac surgery with cardiopulmonary bypass. Br J Anaesth (2004) 0.90
Prescribing for chronic heart failure in Europe: does the country make the difference? A European survey. Pharmacoepidemiol Drug Saf (2007) 0.90
Role of the autonomic nervous system in vagal atrial fibrillation. Heart (2003) 0.90
Agonist-induced down-regulation of type 1 and type 3 inositol 1,4,5-trisphosphate receptors in A7r5 and DDT1 MF-2 smooth muscle cells. Cell Calcium (1998) 0.90
Einthoven dissertation prize 2010. Neth Heart J (2010) 0.89
Feasibility of TEE-guided stroke risk assessment in atrial fibrillation-background, aims, design and baseline data of the TIARA pilot study. Neth Heart J (2011) 0.88
Selective and time related activation of the cardiac renin-angiotensin system after experimental heart failure: relation to ventricular function and morphology. Cardiovasc Res (1993) 0.88
The deletion polymorphism of the angiotensin-converting enzyme gene is related to phenotypic differences in human arteries. Eur Heart J (1996) 0.86
Intracellular angiotensin II elicits Ca2+ increases in A7r5 vascular smooth muscle cells. Eur J Pharmacol (2001) 0.86
Chronic beta-blocker treatment in patients with advanced heart failure. Effects on neurohormones. Int J Cardiol (2000) 0.86
Potentiation of isosorbide dinitrate-induced coronary dilatation by captopril. J Cardiovasc Pharmacol (1987) 0.86
Cardiovascular end-organ damage in Ren-2 transgenic rats compared to spontaneously hypertensive rats. J Mol Med (Berl) (1997) 0.86
Regenerative cell therapy and pharmacotherapeutic intervention in heart failure: Part 1: Cardiovascular progenitor cells, their functions and sources. Neth Heart J (2008) 0.86
Einthoven dissertation prizes 2012. Neth Heart J (2013) 0.86
Atrial fibrillation and sinus node dysfunction. J Am Coll Cardiol (2001) 0.86
Intracellular Angiotensin II and cell growth of vascular smooth muscle cells. Br J Pharmacol (2001) 0.85
Einthoven dissertation prizes 2011. Neth Heart J (2012) 0.85
[Cardiac rehabilitation in patients with a congenital heart disease, an implantable cardioverter defibrillator or chronic heart failure]. Ned Tijdschr Geneeskd (2004) 0.85
Atrial fibrillation: insights from clinical trials and novel treatment options. J Intern Med (2007) 0.85
The isolation and characterization of the promoter of the human type 1 inositol 1,4,5-trisphosphate receptor. Gene (1998) 0.85
Concentration-dependent protection by captopril against myocardial damage during ischemia and reperfusion in a closed chest pig model. J Cardiovasc Pharmacol (1987) 0.85
The importance of microalbuminuria as a cardiovascular risk indicator: A review. Can J Cardiol (2002) 0.85
Coronary artery-bronchial artery fistulas: report of two Dutch cases with a review of the literature. Neth Heart J (2014) 0.85
Comparison of zofenopril and lisinopril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with ACE-inhibitors in experimental heart failure. Br J Pharmacol (2000) 0.85
Routine versus aggressive upstream rhythm control for prevention of early atrial fibrillation in heart failure: background, aims and design of the RACE 3 study. Neth Heart J (2013) 0.84
The presence of an atrial electromechanical delay in idiopathic atrial fibrillation as determined by tissue Doppler imaging. Int J Cardiol (2012) 0.84
Alterations in gene expression of proteins involved in the calcium handling in patients with atrial fibrillation. J Cardiovasc Electrophysiol (1999) 0.84
Statins Do Not Reduce Atrial Fibrillation After Cardiac Valvular Surgery: A Single Centre Observational Study. Neth Heart J (2010) 0.84